Oddo BHF Asset Management Sas Takes $1.11 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Oddo BHF Asset Management Sas purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,629 shares of the medical equipment provider’s stock, valued at approximately $1,110,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. State Street Corp increased its stake in shares of Hologic by 0.8% in the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after purchasing an additional 81,057 shares during the last quarter. FMR LLC grew its position in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after acquiring an additional 18,774 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock worth $200,952,000 after acquiring an additional 195,285 shares during the last quarter. Finally, Black Creek Investment Management Inc. boosted its stake in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after purchasing an additional 885,524 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 1.9 %

Shares of Hologic stock opened at $73.65 on Friday. The stock’s 50-day moving average is $79.32 and its 200 day moving average is $78.59. The firm has a market cap of $16.71 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 2.38 and a beta of 0.96. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a one year low of $70.24 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the company posted $0.89 earnings per share. Equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several research reports. Evercore ISI increased their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Raymond James raised their price objective on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. UBS Group upped their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Mizuho lowered their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $89.50.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.75% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.